ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On November21, 2016, Enanta Pharmaceuticals, Inc. announced via
press release its results for the fiscal year and quarter ended
September30, 2016. A copy of Enantas press release is hereby
furnished to the Commission and incorporated by reference herein
as Exhibit 99.1.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release of Enanta Pharmaceuticals, Inc., dated November21, 2016, reporting Enantas financial results for the fiscal year and quarter ended September30, 2016. |
About ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA)
Enanta Pharmaceuticals Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC). The Company is involved in a program to develop nucleotide inhibitors to HCV NS5B polymerase. In its NASH program, the Company is developing agonists of the farnesoid X receptor, or FXR, that are designed to bind to that receptor and then trigger a response from it. The Company is also engaged in a program in PBC, another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma. Its pipeline of products includes Paritaprevir, ABT-493, EDP-239, ABT-494 and EDP-494. ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) Recent Trading Information
ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA) closed its last trading session up +0.07 at 30.07 with 282,370 shares trading hands.